Abbott Medical Devices
685
38
76
466
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
13.9%
95 terminated/withdrawn out of 685 trials
83.1%
-3.5% vs industry average
9%
64 trials in Phase 3/4
61%
285 of 466 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (685)
Left Bundle Branch Area Pacing (LBBAP) PMCF Study
Role: lead
Cephea Early Feasibility Study
Role: lead
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
Role: lead
Cephea South America Feasibility Study
Role: lead
Abbott Cephea Mitral Valve Disease Registry
Role: lead
TECTONIC CAD IVL IDE Study
Role: lead
Virtual E-health System for Implantable Cardioverter Defibrillators
Role: collaborator
A Post-Market Assessment of the Safety and Performance of the TriClip™ System
Role: lead
Abbott Structural Heart Device Registry
Role: lead
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Role: lead
PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)
Role: collaborator
Amplatzer Amulet China Post Market Study (PMS)
Role: lead
Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea
Role: lead
VOLT-AF IDE Clinical Study
Role: lead
Abbott Medical - VERITAS Study
Role: lead
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Role: lead
Portico Next Generation Approval Study
Role: lead
LEAP 2 Chronic EFS
Role: lead
Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS
Role: collaborator
ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions 2
Role: collaborator